BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BridgeBio Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BridgeBio Pharma's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04988386-11047@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT04988386)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Open-Label Safety Study
  of Acoramidis (AG10) in Symptomatic ATTR Participants\nEstimated primary 
 completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/acoramidis#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04988386
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563895-11047@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT06563895)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Acoramidis Transthyreti
 n Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptoma
 tic Carriers of a Pathogenic TTR Variant\nEstimated primary completion: Oc
 tober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acoramidi
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 563895
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116473-11047@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT07116473)
DESCRIPTION:Attruby (Acoramidis)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: To Evaluate the Long-term Safety and Tolerability
  of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE
 )\nEstimated primary completion: November 2037. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acoramidis#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07116473
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
